Orally dissolving melatonin formulation with acidifying agent that renders melatonin soluble in saliva
US11224658B2 · kind B2 · utility
0Cited by
3References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 13, 2020 |
| Grant date | Jan 18, 2022 |
| Priority date | — |
| Expiry date | May 13, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.